Products Lamivudine is commercially available as film-coated tablets and as an oral solution (3TC, generic, combination). It has been approved in many countries since 1996. Lamivudine is also administered for the treatment of chronic hepatitis B. This article refers to therapy for HIV. Generic medications are approved. Structure and Properties Lamivudine (C8H11N3O3S, Mr = 229.3 … Lamivudine
Products Lamotrigine is commercially available as tablets and dispersible or chewable tablets (Lamictal, generics). It has been approved in many countries since 1994. Vanillin is typically added to the tablets as a flavoring agent and saccharin as a sweetener. Structure and properties Lamotrigine (C9H7Cl2N5, Mr = 256.1 g/mol) is a chlorinated phenyltriazine derivative that was … Lamotrigine (Lamictal)
Products Siponimod was approved in film-coated tablet form in the United States in 2019 and in many countries in 2020 (Mayzent). Structure and properties Siponimod (C29H35F3N2O3, Mr = 516.6 g/mol) is present in the drug as a 2:1 co-crystal with the fumaric acid and as a white powder. The drug was developed starting from fingolimod, … Siponimod
Products Sirolimus (rapamycin) is commercially available as coated tablets and as an oral solution (Rapamune). It has been approved in many countries since 2000. Structure and properties Sirolimus (C51H79NO13, Mr = 914.2 g/mol) is a large, lipophilic and complex molecule. It is a macrocyclic lactone extracted from. This fungus was originally identified in a soil … Sirolimus (Rapamycin)
Products Mycophenolate is commercially available in the form of enteric-coated film-coated tablets (Myfortic). It has been approved in many countries since 2002. Structure and properties Mycophenolate is the deprotonated form of mycophenolic acid (C17H20O6, Mr = 320.3 g/mol). It is present in the drug as mycophenolate sodium, a white crystalline powder that is highly soluble … Mycophenolate
Products Ponatinib is commercially available in film-coated tablet form (Iclusig). It was approved in the EU in 2013 and in many countries in 2014. Structure and properties Ponatinib (C29H27F3N6O, Mr = 532.6 g/mol) is present in the drug as ponatinib hydrochloride, a white to yellow powder whose water solubility decreases with increasing pH. It is … Ponatinib
Products Pomalidomide is commercially available in the form of hard capsules (Imnovid). It has been approved in many countries since 2014. It has been registered in the EU and the United States since 2013. Structure and properties Pomalidomide (C13H11N3O4, Mr = 273.2 g/mol) is an amino derivative of thalidomide and a racemate. It is also … Pomalidomide
Products Linagliptin has been registered as a film-coated tablet in the United States and EU since 2011 and in many countries since 2012 (Trajenta). It went on sale in many countries on May 1, 2012. Linagliptin is also combined fixed with metformin as well as with empagliflozin. Trijardy XR is a fixed combination of empagliflozin, … Linagliptin
Products The fixed combination of the neprilysin inhibitor sacubitril with valsartan was approved in the United States, the EU, and many countries in 2015 in the form of film-coated tablets (Entresto). The combination is also referred to as LCZ696. Structure and properties Sacubitril (C24H29NO5, Mr = 411.5 g/mol) is an ester prodrug that is hydrolyzed … Sacubitril
Products Safinamide is commercially available in the form of film-coated tablets (Xadago). It was approved in many countries and in the EU in 2015 and in the US in 2017. Structure and properties Safinamide (C17H19FN2O2, Mr = 302.3 g/mol) is an α-aminoamide derivative. Effects Safinamide (ATC N04BD03) has indirect dopaminergic properties. It is a selective … Safinamide
Products Delafloxacin was approved in the United States in 2017, in the EU in 2019, and in many countries in 2020 as a powder for a concentrate for solution for infusion and in tablet form (Quofenix). Structure and properties Delafloxacin (C18H12ClF3N4O4, Mr = 440.8 g/mol) belongs to the group of fluoroquinolones. It is present in … Delafloxacin
Products Ozanimod was approved in the United States and many countries in 2020 in hard capsule form (Zeposia). Structure and properties Ozanimod (C23H24N4O3, Mr = 404.5 g/mol) is present in the drug as ozanimod hydrochloride, a white solid that is highly soluble in water. Active metabolites are involved in the effects. Effects Ozanimod (ATC L04AA38) … Ozanimod
